Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial
Introduction - The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients. In this study, we...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 March 2018
|
| In: |
European journal of cancer
Year: 2018, Jahrgang: 94, Pages: 168-178 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2018.02.023 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2018.02.023 Verlag: http://www.sciencedirect.com/science/article/pii/S0959804918302302 
|
| Verfasserangaben: | Y. Gao, B. Weenink, M.J. van den Bent, L. Erdem-Eraslan, J.M. Kros, PAE Sillevis Smitt, K. Hoang-Xuan, A.A. Brandes, M. Vos, F. Dhermain, R. Enting, G.F. Ryan, O. Chinot, M. Ben Hassel, M.E. van Linde, W.P. Mason, J.M.M. Gijtenbeek, C. Balana, A. von Deimling, Th Gorlia, R. Stupp, M.E. Hegi, B.G. Baumert, P.J. French |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1685472028 | ||
| 003 | DE-627 | ||
| 005 | 20240403193310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191213s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2018.02.023 |2 doi | |
| 035 | |a (DE-627)1685472028 | ||
| 035 | |a (DE-599)KXP1685472028 | ||
| 035 | |a (OCoLC)1341282190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gao, Ya |e VerfasserIn |0 (DE-588)1201578752 |0 (DE-627)1685472982 |4 aut | |
| 245 | 1 | 0 | |a Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial |c Y. Gao, B. Weenink, M.J. van den Bent, L. Erdem-Eraslan, J.M. Kros, PAE Sillevis Smitt, K. Hoang-Xuan, A.A. Brandes, M. Vos, F. Dhermain, R. Enting, G.F. Ryan, O. Chinot, M. Ben Hassel, M.E. van Linde, W.P. Mason, J.M.M. Gijtenbeek, C. Balana, A. von Deimling, Th Gorlia, R. Stupp, M.E. Hegi, B.G. Baumert, P.J. French |
| 264 | 1 | |c 20 March 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.12.2019 | ||
| 520 | |a Introduction - The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients. In this study, we performed gene expression profiling on tissues from this trial to identify markers associated with progression-free survival (PFS) and treatment response. - Methods - Gene expression profiling, performed on 195 samples, was used to assign tumours to one of six intrinsic glioma subtypes (IGSs; molecularly similar tumours as previously defined using unsupervised expression analysis) and to determine the composition of immune infiltrate. DNA copy number changes were determined using OncoScan arrays. - Results - We confirm that IGSs are prognostic in the EORTC22033-26033 clinical trial. Specific genetic changes segregate in distinct IGSs: most samples assigned to IGS-9 have IDH-mutations and 1p19q codeletion, samples assigned to IGS-17 have IDH-mutations without 1p19q codeletion and samples assigned to other intrinsic subtypes often are IDH-wildtype. A trend towards benefit from RT was observed for samples assigned to IGS-9 (hazard ratio [HR] for TMZ is 1.90, P = 0.065) but not for samples assigned to IGS-17 (HR 0.87, P = 0.62). We did not identify genes significantly associated with PFS within intrinsic subtypes, although follow-up time is limited. We also show that LGGs and glioblastomas differ in their immune infiltrate, which suggests that LGGs are less amenable to checkpoint inhibitor-type immune therapies. Gene expression analysis also allows identification of relatively rare subtypes. Indeed, one patient with a pilocytic astrocytoma was identified. - Conclusion - IGSs are prognostic for PFS in EORTC22033-26033 clinical trial samples. | ||
| 650 | 4 | |a BELOB | |
| 650 | 4 | |a Gene expression profiling | |
| 650 | 4 | |a Immunophenotype | |
| 650 | 4 | |a Intrinsic subtype | |
| 650 | 4 | |a Low grade glioma | |
| 650 | 4 | |a Pilocytic astrocytoma | |
| 700 | 1 | |a Deimling, Andreas von |d 1959- |e VerfasserIn |0 (DE-588)103034115X |0 (DE-627)735093946 |0 (DE-576)378138065 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 94(2018), Seite 168-178 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial |
| 773 | 1 | 8 | |g volume:94 |g year:2018 |g pages:168-178 |g extent:11 |a Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2018.02.023 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804918302302 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191213 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 103034115X |a Deimling, Andreas von |m 103034115X:Deimling, Andreas von |d 910000 |d 912000 |e 910000PD103034115X |e 912000PD103034115X |k 0/910000/ |k 1/910000/912000/ |p 19 | ||
| 999 | |a KXP-PPN1685472028 |e 3564624961 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Ya","family":"Gao","role":"aut","display":"Gao, Ya"},{"display":"Deimling, Andreas von","family":"Deimling","role":"aut","given":"Andreas von"}],"language":["eng"],"note":["Gesehen am 13.12.2019"],"name":{"displayForm":["Y. Gao, B. Weenink, M.J. van den Bent, L. Erdem-Eraslan, J.M. Kros, PAE Sillevis Smitt, K. Hoang-Xuan, A.A. Brandes, M. Vos, F. Dhermain, R. Enting, G.F. Ryan, O. Chinot, M. Ben Hassel, M.E. van Linde, W.P. Mason, J.M.M. Gijtenbeek, C. Balana, A. von Deimling, Th Gorlia, R. Stupp, M.E. Hegi, B.G. Baumert, P.J. French"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"20 March 2018"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1685472028"],"doi":["10.1016/j.ejca.2018.02.023"]},"recId":"1685472028","title":[{"title_sort":"Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial","title":"Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"language":["eng"],"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"266883400","id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}],"disp":"Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trialEuropean journal of cancer","title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"part":{"extent":"11","text":"94(2018), Seite 168-178","year":"2018","pages":"168-178","volume":"94"}}]} | ||
| SRT | |a GAOYADEIMLEXPRESSION2020 | ||